Increased 9-aminocamptothecin dose requirements in patients on anticonvulsants

Cancer Chemotherapy and Pharmacology

Volumn 42, Issue 2, 1998, Pages 118-126

  Grossman, Stuart A ^a   Hochberg, Fred ^a   Fisher, Joy ^a   Chen, T L ^a   Kim, Lyndon ^a   Gregory, Rebecca ^a   Grochow, Louise B ^a   Piantadosi, Steven ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

9 Aminocamptothecin; Anticonvulsants; Glioblastoma multiforme; High grade astrocytoma; Primary brain tumor

Indexed keywords

9 AMINOCAMPTOTHECIN; ANTICONVULSIVE AGENT; CARBAMAZEPINE; PHENOBARBITAL; PHENYTOIN; VALPROIC ACID;

ADULT; AGED; ARTICLE; ASTROCYTOMA; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INFUSION; FEMALE; GLIOBLASTOMA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SEIZURE;

ADOLESCENT; ADULT; AGED; ANTICONVULSANTS; ANTINEOPLASTIC AGENTS; ASTROCYTOMA; BRAIN NEOPLASMS; CAMPTOTHECIN; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; GLIOBLASTOMA; HUMANS; MIDDLE AGED;

EID: 0031832859     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050794     Document Type: Article

References (43)

1. Afra D, Kocsis B, Szinai I, Eckhardt S (1986) Dibromodulcitol-based combined postoperative chemotherapy of malignant astrocytomas and glioblastomas. J Neurooncol 4: 65-70
2. Afra D, Kerpel-Fronius S, Szinai I, et al (1990) Combined treatment of anaplastic astrocytoma with diacetyl-dianhydrogalactitol (DADAG). J Neurooncol 8: 85-91
3. Bakhemuka M, Massey EW, schoenberg BS (1988) International mortality from primary nervous system neoplasms: distributions and trends: lnt J Epidemiol 17: 33-38
4. Bendixen C, Thomsen B, Alsner J, Wastergaard O (1990) Camptothecin-stabilized topoisomerase I-DNA abducts cause premature termination of transcription. Biochemistry 29: 5613-5619
5. Cairncross G, Macdonald D, Ludwin S, Lee D, Cascino T, Buckner J, Fulton D, Dropcho E, Stewart D, Schold C Jr (1994) Chemotherapy for anaplastic oligodendroglioma. J Clin Oncol 12: 2013-2021
6. Dahut W, Harold N, Takimoto C, Allegra C, Chen A, Hamilton JM, Arbuck S, Sorensen M, Grollman F, Nakashima H, Lieberman R, Liang M, Corse W, Grem J (1996) Phase I and pharmacologic study of 9-aminocamptothecin given by 72-hour infusion in adult cancer patients. J Clin Oncol 14: 1236-1244
7. Dancey J, Eisenhauer EA (1996) Current perspectives on camptothecins in cancer treatment. Br J Cancer 74: 327-338
8. Division of Cancer Treatment, NCI (September 1992) Clinical brochure 9-amino-20(S)-camptothecin (9-AC) NSC 603071
9. Dixit R, Lopez R, Douglas T, Fanska C, Stoltz M, Arneson D, Stedham M, Smith A, Tomaszewski JE (1992) The intravenous infusion toxicity of 9-amino-20[S]-camptothecin (9-AC, NSC-603071) in beagle dogs. Proc Am Assoc Cancer Res 33: 548
10. Fassberg J, Stella VJ (1992) A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues. J Pharm Sci 81: 676-684
11. Fetell MR, Grossman SA, Fisher J, Erlanger B, Rowinsky E, Stockel J, Piantadosi S (1997) Pre-irradiation paclitaxel in glioblastoma multiforme: efficacy, pharmacology, and drug interactions. J Clin Oncol 15: 3121-3128
12. Fine HA, Dear KBG, Loeffler JS, Black PM, Canellos GP (1993) Meta-analysis of radiotherapy with and without adjuvant chemotherapy for malignant gliomas in adults Cancer 71: 2585-2597
13. Giovanella BC, Stehlin JS, Wall ME, Wani Mc, Nicholas AW, Liu LF, Silber R, Potmesil M (1989) DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science 246: 1046-1048
14. Goodman SN, Zahurak ML, Piantadosi S (1995) Some practical improvements in the continual reassessment method for phase 1 studies. Stat Med 14: 1149-1161
15. Greig NH, Reis LG, Yancik R, Rapoport SI (1990) Increasing annual incidence of primary malignant brain tumors in the elderly. J Natl Cancer Inst 82: 1621-1624
16. Grossman SA, Burch PA (1988) Quantitation of tumor response to antineoplastic chemotherapy. Semin Oncol 15: 441-454
17. Grossman SA, Sheidler VR, Gilbert MR (1989) Decreased phenytoin levels in patients receiving chemotherapy: report of a series and a review of the literature. Am J Med 87: 505-510
18. Grossman SA, Wharam M, Sheidler V, Zeltzman M, Zinreich J. Moynihan T, Gilbert H (1992) BCNU, Cisplatin followed by radiation in poor prognosis patients with high grade astrocytomas. Proc Am Soc Clin Oncol 11: 149
19. Hertzberg RP, Caranfa MJ, Hecht S (1989) On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex. Biochem 28: 4629-4638
20. Hildebrand J, Sahmoud T, Mignolet F, Brucher JM, Afra D (1994) Adjuvant therapy with dibromodulcitol and BCNU increases survival of adults with malignant gliomas. Neurology 44: 1479-1483
21. Hsiang YH, Lui LF (1988) Identification of Mammalian DNA topoisomerase 1 as an intracellular target of the anticancer drug camptothecin. Cancer Res 48: 1722-1726
22. Hsiang YH, Hertzberg R, Hecht S, Lin LF (1985) Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260: 14873-14878
23. Levin V, Hoffman WF, Pischer TL, Seager ML, Boldrey EB, Wilson CB (1978) BCNU-5-fluorouracil combination therapy for recurrent malignant brain tumors. Cancer Treat Rep 62: 2071-2076
24. Levin VA, Silver P, Hannigan J, Wara WM, Gutin PH, Davis RL, Wilson CB (1990) Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int J Radiat Oncol Biol Phys 18: 321-324
25. Pantazis P, Hinz HR, Mendoza JT, Kozielski AJ, Williams LJ Jr, Tehlin JS Jr, Giovanella BC (1992) Complete inhibition of growth followed by death of human malignant melanoma cells in vitro and regression of human melanoma xenografts in immunodeficient mice induced by camptothecins. Cancer Res 52: 3980-3987
26. Piantadosi S, Fisher JD, Grossman SA (1998) Practical implementation of the continual reassessment method for dose finding trials. Cancer Chemother Pharmacol 41: 429-436
27. Potmesil M, Giovanella BC, Lui LF (1991) Preclinical studies of DNA topoisomerase I-targeted 9-amino and 10,11-methylenedioxycamptothecin. In: Potmesil M, Kohn KW (eds) DNA topoisomerases in cancer, Oxford University Press, New York, pp 283-298
28. Potmesil M, Giovanella BC, Wall ME, et al (1993) Preclinical and clinical development of DNA topoisomerase 1 inhibitors in the United States. In: Andoh T (ed) The International Symposium on DNA Topoisomerases in Chemotherapy. CRC Press, New York, pp 301-311
29. Rich JN, Grossman SA (1997) Hematologic toxicities associated with hepatically metabolized chemotherapy in brain tumor trials: potential role of anticonvulsants. Proc Am Soc Clin Oncol 16: 395
30. Rivory LP, Robert J (1995) Molecular, cellular and clinical aspects of the pharmacology of 20(S)camplothecin and its derivatives. Pharmacol Ther 68: 269-296
31. Rubin E, Wood V, Bharti A, Trites D, Lynch C, Kufe D (1994) A phase 1 trial of 9-aminocamplothecin (9-AC). Proc Am Assoc Cancer Res 35: 245
32. Slichenmyer WJ, Donehower RC (1995) Recent clinical advances with camptothecin analogues. Cancer Treat Res 78: 29-43
33. Su H, Chen TL, Rowinsky EK (1996) An improved HPLC assay for the determination of plasma 9-aminocamptothecin (9-AC) concentrations in patients with solid tumor in an ongoing phase II clinical trial. Proc Am Assoc Cancer Res 37: 172
34. Supko JG, Malspeis L (1991) A reversed-phase HPLC method for determining camptothecin in plasma with specificity for the intact lactone form of the drug. J Liq Chromatogr 14: 1779-1803
35. Supko JG, Malspeis L (1993) Pharmacokinetics of the 9-amino and 10,11-methylene-dioxy derivatives of camptothecin in mice. Cancer Res 53: 3062-3069
36. Supko JG, Plowman J, Dykes DJ, Zaharko DS (1992) Relationship between the schedule dependence of 9-amino-20-(S)-camptothecin (AC;NSC603071) antitumor activity in mice and its plasma pharmacokinetics. Proc Am Assoc Cancer Res 33: 432
37. Takimoto CH, Klecker RW, Dahut WL, Yee LK, Strong JM, Allegra CJ, Grem JL (1994) Analysis of the active lactone form of 9-aminocamptothecin in plasma using solid-phase extraction and high-performance liquid chromatography. J Chromatogr B Biomed Appl 655: 97-104
38. Takimoto CH, Klecker RW, Dahut WL, Brillhart N, Yee LK, Strong JM, Nakashima H, Lieberman R, Allegra CJ, Grem JL (1994) Preliminary pharmacokinetics of the active lactone form of 9-aminocamptothecin using a sensitive new HPLC assay. Proc Am Assoc Cancer Res 33: 242
39. Takimoto CH, Dahut W, Marino MT, Nakashima H, Liang DM, Harold N, Lieberman R, Arbuck SG, Band RA, Chen AP, Hamilton JM, Cantilena LR, Allegra CJ, Grem JL (1997) Pharmacodynamics and pharmacokinetics of a 72 hour infusion of 9-aminocamptothecin in adult cancer patients. J Clin Oncol 15: 1492-1501
40. Underberg WMJ, Goosen RMJ, Smith BR (1990) Equilibrium kinetics of the new experimental anti-tumor compound SK&F 104864-A in aqueous solution. J Pharm Biomed Anal 8: 681-683
41. Walker MD, Green SB, Byar DP, Alexander E Jr, Batzdorf U, Brooks WH, Hunt WE, Maccarty CS, Mahaley MS Jr, Mealey J Jr, Owens G, Ransohoff J 2nd, Robertson JT, Shapiro WR, Smith KR Jr, Wilson CB, Strike TA (1980) Randomized comparisons of radiotherapy and nitrosoureas for malignant gliomas after surgery. N Engl J Med 303: 1323-1329
42. Wani MC, Ronman PE, Lindley JT, Wall ME (1980) Plant antitumor agents: synthesis and biological activity camptothecin analogues. J Med Chem 23: 554-560
43. Watling CJ, Lee DH, Macdonald DR, Cairncross JG (1994) Corticosteroid-induced magnetic resonance imaging changes in patients with recurrent malignant glioma. J Clin Oncol 12: 1886-1889